

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-61 (Cancelled).

62 (Previously Presented). A method for the treatment of a disease or disorder of the mucosa, the method comprising administering to a subject in need of such treatment a medicament comprising negatively charged lipid assemblies loaded with an active ingredient.

63 (Previously Presented). A method according to Claim 62, wherein the mucosa is the mucosa of the gastrointestinal tract (GI).

64 (Previously Presented). A method according to Claim 62, wherein the lipid assemblies are liposomes.

65 (Previously Presented). The method of Claim 63, wherein said GI mucosa is selected from intestinal mucosa, small bowel mucosa, large bowel mucosa or the mucosa in the rectum.

66 (Previously Presented). The method of Claim 65, wherein said mucosa is the intestinal mucosa.

67 (Previously Presented). The method of Claim 62, wherein said lipid assemblies comprise one or more anionic lipids selected from 1,2-distearoyl-*sn*-glycero-3-[phospho-*rac*-(1-glycerol)] (DSPG), hydrogenated soy phosphoglycerol.

68 (Previously Presented). The method of Claim 62, wherein said disease or disorder is associated with a condition selected from inflammation and long term oxidative stress short term oxidative stress

69 (Previously Presented). A method according to Claim 68, wherein the disease or disorder is selected from ulcerative colitis, Crohn's disease, gastric ulceration, duodenal ulceration, ileitis, colitis, ileocolitis, ulcerative proctitis, gastroenteritis, diverticulitis, diverticulosis, reflux, ulcer, gastritis, dyspepsia, nausea, abrasion to gastrointestinal tract.

70 (Previously Presented). The method of Claim 68, wherein said disease or disorder is associated with inflammation, and said medicament comprises an active ingredient is an agent effective in inhibiting inflammatory responses.

71 (Previously Presented). A method according to Claim 70, wherein the active agent is selected from: steroids, salicylates, COX-2 inhibitors, anti-TNF $\alpha$  drugs, antibiotics, immunosuppressors, immunomodulators and antioxidants.

72 (Previously Presented). A method according to Claim 71, wherein the active agent is selected from Prednisone, Prednisolone, methylprednisolone, methylprednisolone succinate, Budesonide, derivatives of 5-aminosalicylic acid, Sulfasalazine. Mesalamine (5ASA), Olsalazine Balsalazide, Metronidazole Ciprofloxacin, Probiotics g. Cyclosporin A, Azathioprine, Methotrexate and 6-Mercaptopurine

73 (Previously Presented). The method of Claim 68, wherein said disease or disorder is associated with oxidative stress, and said medicament comprises as an active ingredient one or more anti-oxidants.

74 (Previously Presented). The method of claim 73 wherein the active agent is selected from tocopherol, free radicals scavengers, SOD and SOD mimics, catalase or therapeutic reducing agents

75 (Previously Presented). The method of Claim 68, wherein said disease or disorder is selected from ulcerative

Appln. No. 10/578,090

Response. dated May 17, 2010

Reply to Office Action of: April 16, 2010

colitis, Crohn's disease, irritable bowel syndrome, colon carcinoma and familial adenomatous polyposis.

76-79 (Cancelled).